Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Eligible eyes are randomized to two groups. Group A will receive three intravitreal
injections of bevacizumab at 4 week intervals. In group B, three intravitreal injections of
combined bevacizumab and fasudil will be performed with the same frequency.
Best corrected visual acuity (BCVA) and central macular thickness (CMT) will be evaluated
prior to injections and then every 4 weeks for 6 months. Fluorescein angiography will be
performed at baseline and at weeks 12 and 24. The two groups will be compared in terms of
BCVA and CMT changes.